News

The NIH Proteus syndrome team is led by researchers who originally discovered the somatic single (point) mutation in the AKT 1 oncogene that causes Proteus syndrome. On that

In the initial phase of the clinical program scheduled to commence this month, eight (8) DKD patients will be enrolled. The objectives of this double blind, placebo controlled,

New, detailed results from part one of the Phase 2 portion of AbbVie’s Phase 2/3 open-label study, TURQUOISE-I, showed that patients co-infected with genotype 1 (GT1) HCV and

Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the

As a company spokesperson for AdeptNature explained, the Premium Phytoceramides Capsules for Skin is an all-natural product that can help to soften, firm up and make skin look

Around 316 healthy adults aged 18-40 were enrolled in the Phase I trial and they were each evaluated for vaccine tolerability and immune response at 21 days post-vaccination.

The Israeli firm is a developer, manufacturer and marketer of new bio-active lipid based nutritional ingredients and medical foods. Around 171 patients between the ages of 18 and

As part of the deal, BioAtla will direct BioDuro’s efforts to advance these compounds through the preclinical and Phase I clinical phases and each candidate will be licensed

Stellar is a manufacturer of KLH, an immune-stimulating protein widely used as a carrier molecule in the development of immunotherapies. Spain-based Araclon is majority-owned by global healthcare firm